The debates of the Constitutional Convention of the state of Iowa, assembled at Iowa City, Monday, January 19, 1857. Being a full and complete report of the debates and proceedings, by authority of the Convention; accompanied, for purposes of reference, by a copious index of subjects, and remarks of members thereon. W. Blair Lord, reporter.

The two volume record of the debates that occured during the thirty-nine days it took to draft the third constitution of the State of Iowa.

Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.

Background: Sagopilone (ZK 219477), a lipophylic and synthetic analog of epothilone B, that crosses the blood-brain barrier has demonstrated preclinical activity in glioma models.Patients and methods: Patients with first recurrence/progression of glioblastoma were eligible for this early phase II and pharmacokinetic study exploring single-agent sagopilone (16 mg/m(2) over 3 h every 21 days). Primary end point was a composite of either tumor response or being alive and progression free at 6 months. Overall survival, toxicity and safety and pharmacokinetics were secondary end points.Results: Thirty-eight (evaluable 37) patients were included. Treatment was well tolerated, and neuropathy occurred in 46% patients [mild (grade 1) : 32%]. No objective responses were seen. The progression-free survival (PFS) rate at 6 months was 6.7% [95% confidence interval (CI) 1.3-18.7], the median PFS was just over 6 weeks, and the median overall survival was 7.6 months (95% CI 5.3-12.3), with a 1-year survival rate of 31.6% (95% CI 17.7-46.4). Maximum plasma concentrations were reached at the end of the 3-h infusion, with rapid declines within 30 min after termination.Conclusions: No evidence of relevant clinical antitumor activity against recurrent glioblastoma could be detected. Sagopilone was well tolerated, and moderate-to-severe peripheral neuropathy was observed in despite prolonged administration.

Síntesi i optimització de la DPTMephos. Complexos de Mo i W

La ruta sintètica del bis(2-((difenilfosfino)metil)fenil)sulfà, Ph2PCH2-(C6H4)S(C6H4)-CH2PPh2 , DPTMephos, involucra 5 reaccions en 4 etapes ben diferenciades. Es per aquest motiu que es fa necessària una optimització de la ruta sintètica per assolir rendiments més elevats. La primera reacció parteix del sulfur de difenil i involucra la formació d’un complex litiat per acabar realitzant una carbonilació amb N,N-DMF per obtindre un dialdehid. El següent pas de la ruta passa per la reducció del producte al diol corresponent. Tot seguit ja es por preparar el substrat mitjanjant una bromació per a que en l’última etapa, s’acobli a l’estructura el grup difenilfosfino. Tant mateix s’han sintetitzat els isòmers de la DPTMephos amb [W(CO)6] i [Mo(CO)6], observant-se la formació tant dels complexos meridionals com facials i la seva interconversió. Tot seguit s’ha desenvolupat la sulfuració de la DPTMephos per obtindre els lligands tant mono com di sulfurats. També s’ha realitzat un estudi de l’espectre de RMN 31P{1H} del complex fac-[Mo(CO)3(DPTMephos)] a temperatura variable per determinar el senyal de cada fòsfor no equivalent a 200K. S’ha realitzat un estudi de forma qualitativa de les conformacions que adopta l’anell quelat de 6 baules en les conformacions tant meridional com facial d’un complex.

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

Resistance to alkylating agents via direct DNA repair by O(6)-methylguanine methyltransferase (MGMT) remains a significant barrier to the successful treatment of patients with malignant glioma. The relative expression of MGMT in the tumor may determine response to alkylating agents, and epigenetic silencing of the MGMT gene by promoter methylation plays an important role in regulating MGMT expression in gliomas. MGMT promoter methylation is correlated with improved progression-free and overall survival in patients treated with alkylating agents. Strategies to overcome MGMT-mediated chemoresistance are being actively investigated. These include treatment with nontoxic pseudosubstrate inhibitors of MGMT, such as O(6)-benzylguanine, or RNA interference-mediated gene silencing of MGMT. However, systemic application of MGMT inhibitors is limited by an increase in hematologic toxicity. Another strategy is to deplete MGMT activity in tumor tissue using a dose-dense temozolomide schedule. These alternative schedules are well tolerated; however, it remains unclear whether they are more effective than the standard dosing regimen or whether they effectively deplete MGMT activity in tumor tissue. Of note, not all patients with glioblastoma having MGMT promoter methylation respond to alkylating agents, and even those who respond will inevitably experience relapse. Herein we review the data supporting MGMT as a major mechanism of chemotherapy resistance in malignant gliomas and describe ongoing studies that are testing resistance-modulating strategies.

Catalogue de miniatures..., tableaux... provenant du cabinet de M. W... [Walferdin] / [expert] Vignères

[Vente. Art. 1860-05-18. Paris]

Mètriques barrier walkthrough per a persones sordes

En aquest article es presenta un conjunt de mètriques manuals, les mètriques BAW, per avaluar l'accessibilitat web d'una pàgina dins d'un context específic i ofereix la possibilitat de quantificar el grau d'accessibilitat amb una fórmula.

[80 phot. des îles Shetland, Orcades, Skye, Bute et autres îles du nord-ouest de l'Ecosse, par G.W. Wilson, don E. Saisset en 1886]

Donateur : Saisset, E. (18..-18..?)